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Abstract
Purpose For postmenopausal patients with hormone receptor-positive early breast cancer, the optimal subgroup and dura-
tion of extended endocrine therapy is not clear yet. The aim of this study using the IDEAL patient cohort was to identify 
a subgroup for which longer (5 years) extended therapy is beneficial over shorter (2.5 years) extended endocrine therapy.
Methods In the IDEAL trial, 1824 patients who completed 5 years of adjuvant endocrine therapy (either 5 years of tamox-
ifen (12%), 5 years of an AI (29%), or a sequential strategy of both (59%)) were randomized between either 2.5 or 5 years 
of extended letrozole. For each prior therapy subgroup, the value of longer therapy was assessed for both node-negative and 
node-positive patients using Kaplan Meier and Cox regression survival analyses.
Results In node-positive patients, there was a significant benefit of 5 years (over 2.5 years) of extended therapy (disease-free 
survival (DFS) HR 0.67, p = 0.03, 95% CI 0.47–0.96). This effect was only observed in patients who were treated initially 
with a sequential scheme (DFS HR 0.60, p = 0.03, 95% CI 0.38–0.95). In all other subgroups, there was no significant benefit 
of longer extended therapy. Similar results were found in patients who were randomized for their initial adjuvant therapy 
in the TEAM trial (DFS HR 0.37, p = 0.07, 95% CI 0.13–1.06), although this additional analysis was underpowered for 
definite conclusions.
Conclusions This study suggests that node-positive patients could benefit from longer extended endocrine therapy, although 
this effect appears isolated to patients treated with sequential endocrine therapy during the first 5 years and needs validation 
and long-term follow-up.
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Introduction
In hormone receptor-positive (HR+) breast cancer, adju-
vant endocrine therapy is used to decrease the risk for 
recurrence, and improve the overall survival (OS). Where 
tamoxifen for 5 years has been the standard adjuvant endo-
crine therapy for a long period of time, currently, treatment 
regimens for adjuvant endocrine therapy are mostly based 
on 5 years of an aromatase inhibitor (AI), or a sequential 
strategy of tamoxifen followed by an AI. Among others, the 
Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
trial showed that after 5 and 10 years of follow-up, there 
was no difference in disease-free survival (DFS) between 
patients randomized to either tamoxifen followed by exemes-
tane or exemestane monotherapy [1, 2]. These results were 
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confirmed in a meta-analysis performed by the Early Breast 
Cancer Trialists Collaborative Group (EBCTCG) [3].
Despite the value of adjuvant endocrine therapy, it is 
known that the risk for recurrence in HR+ breast cancer 
remains linear up to at least 15 years after diagnosis prompt-
ing to study the value of extended endocrine therapy. After 
5 years of tamoxifen, it has been established that extended 
therapy beyond 5 years leads to a modest reduction in recur-
rences, but not in overall survival [4, 5]. This has been par-
ticularly observed for patients with node-positive disease 
[6].
The value of extended endocrine therapy after a 5 years 
regimen including an AI (either upfront or after 2–3 years 
of tamoxifen) is less clear. Recently, three independent stud-
ies did not show a significant benefit of (longer) extended 
endocrine therapy for the total study population [7–9]. In 
the NSABP B-42 trial, patients who earlier received either 
5 years of an AI, or a sequential treatment of tamoxifen fol-
lowed by an AI until 5 years, were randomized between 
5 years of extended letrozole or placebo. After 5 years, there 
was no significant benefit of 5 years of letrozole over pla-
cebo. In the subgroup analysis, however, a significant benefit 
for patients who received prior tamoxifen followed by an AI 
(HR 0.75, p = 0.04) was found, which was not observed in 
patients who were treated upfront with AI monotherapy for 
5 years (HR 0.91, p = 0.34) [7].
In the Dutch ‘Investigation on the Duration of Extended 
Adjuvant Letrozole treatment’ (IDEAL) trial, 1824 post-
menopausal patients, who received any form of primary 
adjuvant endocrine therapy for 5 years, were randomized 
between extended letrozole for 2.5 or 5 years. The results of 
this trial were published recently by our group, and identi-
fied no subgroup that benefitted significantly from 5 instead 
of 2.5 years of extended therapy [9]. In the IDEAL trial, 
approximately 60% was treated initially with the sequen-
tial scheme, whereas 30% was treated with an upfront aro-
matase inhibitor only, and approximately 10% was treated 
with tamoxifen monotherapy.
In the Dutch study on ‘Duration of Anastrozole therapy 
after 2–3 years Tamoxifen as Adjuvant therapy’ (DATA), 
postmenopausal patients were randomized after 2–3 years 
of tamoxifen between 3 years of anastrozole (standard arm, 
duration of endocrine therapy 5–6 years in total) or 6 years 
of anastrozole (extended duration, 8–9 years in total). Also 
in this trial, no effect of extended AI (anastrozole) therapy 
was shown for the total population. However, this study did 
observe a significant benefit of longer AI therapy in high-
risk subgroups, in particular, in patients with lymph-node-
positive disease [8].
Combining the conclusions on the subgroup analy-
ses of the NSABP B-42 and DATA trials, it is suggested 
that extended therapy might be the most beneficial for 
node-positive patients who were previously treated with 
tamoxifen followed by an AI. However, the optimal dura-
tion of extended therapy is not clear, since the regimens and 
populations in both trials differ too much for direct compari-
sons. In view of the above-mentioned data, we performed an 
additional subgroup analysis in the IDEAL trial. The aims 
of the current subanalyses were to investigate the effects of 
primary adjuvant treatment and nodal status on the optimal 
duration of extended adjuvant endocrine therapy. Further-
more, similar analyses were conducted in the subgroup of 
patients that previously participated in the TEAM trial, as 
this subgroup was randomized for the initial therapy.
Methods
IDEAL trial cohort
In the phase-3 IDEAL trial, 1824 postmenopausal patients 
were randomized at diagnosis between 2.5 or 5 years of 
letrozole, after 5 years of any type of adjuvant endocrine 
therapy for early HR+ breast cancer. Patients needed to be 
disease free at the moment of randomization. Furthermore, 
a maximum of 2 years was allowed between finishing ear-
lier endocrine therapy and starting extended therapy. As the 
treatment arms during the first 2.5 years were equal, no dif-
ferences can be expected during this period. Therefore, for 
the current analysis, patients that encountered an event or 
stopped therapy during the first 2.5 years were excluded, and 
the survival analysis started at 2.5 years after randomization 
at which time point the treatment arms diverge. Details of 
the trial, data collected, and the primary results have recently 
been reported elsewhere [9, 10].
A total of 438 IDEAL patients (24%) also participated 
in the TEAM trial during the first 5 years of their adjuvant 
endocrine therapy. In this phase-III study, postmenopausal 
patients with early HR+ breast cancer were randomized at 
diagnosis between 5 years of exemestane, or 2.5 years of 
tamoxifen followed by 2.5 years of exemestane (sequential 
scheme). In case they were disease free and finished 5 years 
of therapy, and their hospital participated in the IDEAL trial, 
they were eligible for inclusion in the IDEAL trial. In order 
to correct for a possible allocation bias in the distribution 
of previous endocrine therapy between node-negative and 
node-positive patients, all analyses were repeated in the 
cohort of patients that participated in the TEAM trial as 
these patients were not subjected to allocation bias due to 
the randomization already at primary diagnosis.
The IDEAL trial is registered in the Netherlands with 
the Netherlands Trial Register, NTR3077, the Dutch Breast 
Cancer Research Group (BOOG 2006-05) and Eudra-CT 
2006-003958-16. The original study was conducted in com-
pliance with the guidelines of the Declaration of Helsinki, 
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International Conference on Harmonisation and Good Clini-
cal Practice.
Endpoints
The primary endpoint of the IDEAL trial was disease-free 
survival (DFS) defined as the time from randomization to 
recurrence (either local, regional, or distant), new primary 
breast tumors (DCIS or invasive) or death due to any cause. 
For the current analysis, DFS was also the primary study 
endpoint, with follow-up starting at 2.5 years after rand-
omization with a 10% margin. The secondary outcomes for 
this analysis were overall survival (OS), defined as time 
to death due to any cause starting at 2.5 years after ran-
domization, and distant metastasis-free interval (DMFi), 
defined as time to distant recurrence starting at 2.5 years 
after randomization.
Statistical analysis
The analyses for primary and secondary outcomes (DFS, 
OS, and DMFi) of the current study were performed using 
Kaplan–Meier analysis, stratified for the type of endocrine 
therapy during the first 5 years, and nodal status at diagnosis. 
Hazard ratios (HRs) and treatment-by-marker interactions 
were estimated using Cox regression analysis.
Results
Cohorts
Of the 1824 postmenopausal patients enrolled in the IDEAL 
trial, 1339 were disease free and on letrozole therapy at 
2.5 years after randomization, and were eligible for the cur-
rent analysis. There were no significant differences in patient 
baseline characteristics between the randomized treatment 
arms in this subcohort (Table 1).
Of the 438 patients who also participated in the TEAM 
trial, 311 patients were disease free and on therapy at 
2.5 years after randomization in the IDEAL study, and 
therefore eligible for our additional analysis. Patient char-
acteristics of the IDEAL-only and IDEAL/TEAM patients 
are described in Table 2. Compared with the IDEAL-only 
cohort (not participating in TEAM), IDEAL/TEAM patients 
were significantly older at randomization, more often 
treated with breast conserving therapy (55% vs. 47.5%, X2 
p = 0.037) and less often treated with chemotherapy (42.1% 
vs. 77.6%) (Table 2).
Regarding the prior endocrine therapy strategy, 816 
IDEAL patients (60.9%) were treated with a sequen-
tial scheme of tamoxifen followed by an AI, 369 patients 
(27.6%) were treated with AI monotherapy, and 154 patients 
(11.5%) were treated with tamoxifen monotherapy. In the 
TEAM subgroup, 46.3% was treated with a sequential 
scheme, and 52.4% with AI monotherapy, as expected due 
to the TEAM trial design. Another four TEAM patients were 
treated with tamoxifen monotherapy because of refusal of 
switch to AI after 2.5 years of tamoxifen.
Table 1  Characteristics of the IDEAL study cohort of patients who 
were disease free and on therapy after 2.5 years of extended treatment
2.5 years 5 years
N % N %
Age at randomisation
 < 55 years 191 28.6 197 29.4
 55–65 years 288 43.0 283 42.2
 65–75 years 151 22.6 136 20.3
 > 75 years 39 5.8 54 8.1
Nodal status
 pN0/pN0(i+) 176 26.3 171 25.5
 pN1(mi)/N1/N2/N3 493 73.7 499 74.5
Tumor type
 Ductal 508 75.9 547 81.6
 Mucinous 5 0.7 6 0.9
 Medullar 1 0.1 2 0.3
 Lobular 113 16.9 87 13.0
 Other/unknown 42 6.2 28 4.2
Histological grade
 Grade 1 115 17.2 102 15.2
 Grade 2 278 41.6 281 41.9
 Grade 3 205 30.6 217 32.4
 Gx 71 10.6 70 10.4
Progesteron receptor status
 Negative 113 16.9 136 20.3
 Positive ≥ 10% 528 78.9 510 76.1
HER2 status
 Negative 242 36.2 246 36.7
 Positive 67 10.0 63 9.4
 Unknown 360 53.8 309 53.9
Performed final surgery
 Breast conserving 335 50.1 324 48.4
 Mastectomy 331 49.5 344 51.3
Prior chemotherapy
 No 212 31.7 198 29.6
 Yes 457 68.3 472 70.4
Prior endocrine treatment
 5 years tamoxifen 76 11.4 78 11.6
 5 years AI 177 26.5 192 28.7
 2–3 years tam- > 3–2 years AI 416 62.2 400 59.7
Time after stop hormonal therapy (months)
 0– < 6 602 90.0 610 91.0
 6– < 12 30 4.5 27 4.0
 12–27 37 5.5 33 4.9
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Main subgroup analysis in all patients
In the total selected IDEAL patient group (n = 1339), 167 
patients encountered a DFS event during follow-up (median 
follow-up of 7 years, including the first 2.5 years).
For node-negative patients, no benefit of longer endocrine 
therapy was found (HR 1.53, p = 0.16, 95% CI 0.84–2.80). 
In contrast, for node-positive patients we observed a benefi-
cial effect of longer extended therapy (HR 0.67, p = 0.03, 
95% CI 0.47–0.96), with a HR for interaction between nodal 
subgroups of 0.44 (95% CI 0.22–0.88, p = 0.02) (Table 3, 
Fig. 1).
When stratified for nodal status and type of endocrine 
therapy during the primary adjuvant therapy, we only 
observed the benefit of 5 years over 2.5 years of letrozole for 
node-positive patients in patients treated with prior sequen-
tial endocrine therapy (8 year DFS after randomization 89% 
vs. 83.4%, HR 0.61, p = 0.037, 95% CI 0.38–0.97) (Fig. 2). 
In this subgroup, the p value for the treatment by subgroup 
interaction test based on nodal status was 0.05, indicating a 
significantly higher treatment effect in node-positive com-
pared to node-negative patients. In all other considered sub-
groups, no benefit of longer extended therapy was observed 
(Table 3).
For the endpoint DMFi, similar results were observed 
(Table 3). In node-positive patients previously treated with 
sequential therapy, a benefit of 5 over 2.5 years of letro-
zole was shown (HR 0.50, p = 0.03, 95% CI 0.27–0.94), but 
no differential effect between the treatment durations was 
observed for all other subgroups (p for interaction 0.14). For 
the endpoint OS, no benefit of longer extended therapy was 
shown for any of the subgroups (Table 3).
Additional subgroup analysis in TEAM patients
With respect to the additional analysis in the TEAM patient 
subgroup (n = 311), 50 patients had a DFS event, of which 
19 were DMFi events and 31 OS events. For DFS, a benefit 
of longer extended therapy was observed for node-positive 
patients pretreated with sequential therapy, however, with-
out statistical significance (8 year DFS after randomization 
90% vs. 76.1%, HR 0.37, p = 0.07, 95% CI 0.13–1.06). For 
DMFi, a similar nonsignificant benefit of longer therapy was 
found for the same subgroup (HR 0.14, p = 0.07, 95% CI 
0.02–1.15). Regarding OS, no benefit was realized for any 
of the subgroups (Table 3).
Discussion
In this analysis of IDEAL patients, we found a significant 
benefit of longer (5 vs. 2.5 years) extended letrozole ther-
apy on disease-free and distant-metastasis-free survival, 
for node-positive patients, and in particular for those who 
received sequential adjuvant endocrine therapy during the 
first 5 years. In contrast, patients treated with AI monother-
apy had no benefit of longer extended therapy, irrespective 
of nodal status. For overall survival, no significant benefit 
Table 2  Characteristics of the IDEAL patients that participated ear-
lier in the TEAM trial
Participation in TEAM trial
No Yes X2 p value
N % N %
Age at randomisation
 < 55 years 380 37.0 8 2.6 < 0.001
 55–65 years 445 43.3 126 40.5
 65–75 years 163 15.9 124 39.9
 > 75 years 40 3.9 53 17.0
Nodal status
 pN0/pN0(i +) 273 26.6 74 23.8 0.33
 pN1(mi)/N1/N2/N3 755 73.4 237 76.2
Tumor type
 Ductal 803 78.1 252 81.0 0.84
 Mucinous 9 0.9 2 0.6
 Medullar 2 0.2 1 0.3
 Lobular 160 15.6 40 12.9
 Other/unknown 54 5.3 16 5.1
Histological grade
 Grade 1 161 15.7 56 18.0 0.06
 Grade 2 422 41.1 137 44.1
 Grade 3 322 31.3 100 32.2
 Gx 123 12.0 18 5.8
Progesteron receptor status
 Negative 179 17.4 70 22.5 0.19
 Positive ≥ 10% 807 78.5 231 74.3
HER2 status
 Negative 403 39.2 85 27.3 < 0.001
 Positive 125 12.2 5 1.6
 Unknown 500 48.6 221 71.1
Performed final surgery
 Breast conserving 488 47.5 171 55.0 0.04
 Mastectomy 535 52.0 140 45.0
Prior chemotherapy
 No 230 22.4 180 57.9 < 0.001
 Yes 798 77.6 131 42.1
Prior endocrine treatment
 5 years tamoxifen 150 14.6 4 1.3 < 0.001
 5 years AI 206 20.0 163 52.4
 2–3 years tam- > 3–2 years AI 672 65.4 144 46.3
Time after stop hormonal therapy (months)
 0– < 6 928 90.3 284 91.3 0.63
 6– < 12 43 4.2 14 4.5
 12–27 57 5.5 13 4.2
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of longer extended letrozole was observed in any subgroup, 
although the follow-up is relatively short for definite conclu-
sions hereon.
The distribution of patients pretreated with tamox-
ifen (followed by an AI) or with AI monotherapy in the 
full IDEAL cohort might have been subject to allocation 
bias. Therefore, we performed an additional analysis in the 
IDEAL patients who also participated in the TEAM trial. 
Using the randomization of the TEAM trial, we balanced the 
previous endocrine therapy subgroups for baseline charac-
teristics. In this additional analysis, similar numerical results 
were observed, although without statistical significance. 
This is most likely explained by the lack of power due to 
the smaller population size, and the low number of events 
in general. However, the similarity between the HRs for the 
total IDEAL cohort and the TEAM subgroup indicates that 
the results from the IDEAL cohort are not explained by an 
allocation bias.
The observation that (longer) extended therapy was only 
of value for node-positive patients, being at higher risk of 
recurrent disease, is in line with previous observations. In 
a meta-analysis by Ibrahim et al., in which all patients were 
pretreated with tamoxifen monotherapy, a subgroup analy-
sis showed that the positive effect of extended endocrine 
therapy on breast cancer recurrence was only observed in 
node-positive patients (OR 0.70, 95% CI 0.58–0.84), and not 
in node-negative patients (OR 0.96, 95% CI 0.71–1.29) [6]. 
Remarkably, in our analysis there was no benefit of longer 
extended therapy in either node-negative or node-positive 
patients that were treated with tamoxifen monotherapy. 
However, tamoxifen monotherapy for the first 5 years was 
not considered as standard therapy anymore during the con-
duct of the IDEAL trial, and most likely there might have 
been a selection bias of very-low-risk patients who remain 
on tamoxifen after 2–3 years instead of switching to an AI. 
In these low-risk patients, a benefit of extended therapy 
is unlikely. Furthermore, tamoxifen monotherapy as prior 
endocrine therapy was a very small subgroup (12%) in the 
IDEAL trial, leading to a lack of power for conclusions in 
this subgroup.
The results of our analysis suggest that when patients 
were pretreated with AI monotherapy for 5 years, there 
was no additional effect of 5 over 2.5 years of extended AI 
therapy. A possible explanation could be that the maximal 
treatment effect of aromatase inhibitors is reached after 
approximately 7.5 years. Therefore, after 5 years of AI 
monotherapy, an additional 5 years would have no benefit 
over 2.5 years. However, the results from this relative small 
subgroup analysis need to be interpreted with care, and 
should be validated in a meta-analytical setting before final 
conclusions can be drawn.
In all node-negative subgroups, there is a trend toward 
worse outcome for longer therapy, although none of these 
effects are statistically significant (Table 3). For overall sur-
vival, this might be explained by the fact that in this low-
risk subgroup, letrozole adverse events possibly leading to 
mortality outweigh the benefit of letrozole on breast cancer-
related mortality. However, this does not explain why we see 
the same trend for longer therapy on distant metastasis-free 
interval. Further evaluations in larger analyses from collabo-
rative groups, in the setting of a meta-analysis, are required 
to validate this effect.
A limitation of this trial is that the analyses were per-
formed in a subgroup of the original trial population, and 
this subgroup analysis was therefore not powered to detect 
small differences and might have suffered from multiple-
testing error. Furthermore, in view of the design of the 
IDEAL study (having two treatment arms and no placebo 
Log-rank p=0.16 Log-rank p=0.03
2.5 years 176 168 113 28 493 461 317 98
5 years 171 163 105 30 499 474 334 104
N0 N+
Fig. 1  Kaplan–Meier analysis for disease-free survival of all patients that were disease free and on therapy after 2.5 years, stratified for nodal 
status. Log-rank tests were used to assess the differences between treatment arms for each subgroup (reported as p values)
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arm), it was not possible to investigate the value of extended 
therapy versus no extended therapy.
In conclusion, the results of the current exploratory 
analysis in IDEAL patients suggest that longer (vs. shorter) 
extended endocrine therapy might be of value for node-pos-
itive patients, and in particular for those who were treated 
with tamoxifen followed by an AI for the first 5 years, which 
was not observed in the AI monotherapy subgroup. For all 
node-negative patients, there was no beneficial effect of 
longer therapy, and even a trend toward a worse outcome. 
Future studies, and future meta-analyses, are warranted to 
validate these results, and to further identify for which sub-
group there is an effect of extended endocrine therapy after 
optimal endocrine therapy over the first 5 years.
N0 N+
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Log-rank p=0.62 Log-rank p=0.81
Log-rank p=0.25 Log-rank p=0.52
Log-rank p=0.03Log-rank p=0.35
2.5 years 23 22 18 9 53 52 40 20
5 years 25 24 21 11 53 53 39 19
2.5 years 50 47 25 5 127 122 76 15
5 years 53 50 25 5 139 131 78 18
2.5 years 103 100 72 16 313 289 203 65
5 years 93 90 61 16 307 292 219 69
Fig. 2  Kaplan–Meier analysis of the main analysis in all patients that 
were disease free and on therapy after 2.5 years. Results are shown 
for disease-free survival, for the subgroups stratified on prior endo-
crine therapy and nodal status. Log-rank tests were used to assess the 
differences between treatment arms for each subgroup (reported as p 
values)
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